Lapatinib（GW572016）对ErbB-2和EGFR酪氨酸激酶结构域具有强效抑制作用，对纯化EGFR和ErbB-2的IC50值分别为10.2 nM和9.8 nM。

Afatinib（BIBW 2992）是一种口服活性强且不可逆的ErbB家族（EGFR和HER2）双特异性抑制剂，对EGFRwt、EGFRL858R、EGFRL858R/T790M和HER2的IC50值分别为0.5 nM、0.4 nM、10 nM和14 nM。阿法替尼用于研究食管鳞状细胞癌（ESCC）、非小细胞肺癌（NSCLC）和胃癌。

Neratinib（HKI-272）是一种口服可用的、不可逆的、高度选择性的HER2和EGFR抑制剂，对其IC50值分别为59 nM和92 nM。

Canertinib is a pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM, no activity to PDGFR, FGFR, InsR, PKC, or CDK1/2/4.

Dacomitinib is a potent, orally available, irreversible tyrosine kinase HER 1 (EGFR), HER2 and HER4 inhibitor with IC50 of 6, 45.7 and 73.7 nM for EGFR, ERBB2 and ERBB4, respectively.

AZD8931 is a reversible, ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 with IC50 of 4 nM, 3 nM and 4 nM respectively.

CUDC-101是一种强效的HDAC、EGFR和HER2抑制剂，IC50值分别为4.4、2.4和15.7 nM。它是一种包含炔基的砌块化学探针，用于铜催化的偶联反应（CuAAc）。

Pelitinib irreversiblly inhibits EGFR with IC50 of 38.5 nM.

Allitinib tosylate（AST-1306（TsOH））是一种口服活性和不可逆的EGFR和ErbB2抑制剂，其IC50值分别为0.5和3 nM。Allitinib tosylate以0.8 nM的IC50抑制ErbB4，是一种具有抗癌活性的苯基氨基喹唑啉化合物。

Varlitinib is a selective and potent ErbB1 (EGFR) and ErbB2 (HER2) inhibitor with IC50 of 7 nM and 2 nM, respectively.

TAK-285 is a dual HER2 and EGFR (HER1) inhibitor with IC50 of 17 nM and 23 nM, > 10-fold selectivity for HER1/2 than HER4, less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc.

AST-1306 is an irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R, more potent to ErbB2-overexpressing cells, 3000-fold selective for ErbB family than other kinases.

EGFR/ErbB-2/ErbB-4 inhibitor-2是一种三重靶向抑制剂，能够有效抑制 EGFR、ErbB-2 和 ErbB-4，应用于癌症治疗研究中。

Tuxobertinib是一种针对 EGFR 和 HER2 变构突变的抑制剂，在多种癌症治疗中表现出显著的抗肿瘤效果。

Irbinitinib is a potent and selective HER2 inhibitor with IC50 of 8 nM, equipotent against truncated p95-HER2, 500-fold selective for HER2 versus EGFR.

Afatinib dimaleate（BIBW 2992）二马来酸盐是一种口服活性、高效且不可逆的ErbB家族（EGFR和HER2）双特异性抑制剂，对EGFRwt、EGFRL858R、EGFRL858R/T790M和HER2的IC50分别为0.5 nM、0.4 nM、10 nM和14 nM。它用于食管鳞状细胞癌（ESCC）、非小细胞肺癌（NSCLC）和胃癌的研究。

Poziotinib is an irreversible Pan-HER inhibitor with IC50s of 3/5/23 nM for HER1/HER2/HER4 respectively.

AV-412 是一种有效的 EGFR 和 ErbB2 (IC50=19 nM) 酪氨酸激酶的双重抑制剂，包括突变型 EGFR (L858R IC50=0.51 nM, T790M IC50=0.79 nM)。它抑制 EGFR 和 ErbB2 的自磷酸化，IC(50) 分别为 43 nM 和 282 nM。

ARRY-380 analog is a potent and selective HER2 inhibitor with IC50 of 8 nM, equipotent against truncated p95-HER2, 500-fold selective for HER2 versus EGFR.

AEE788 is an inhibitor of both EGFR and VEGFR, the IC50s for EGFR and ErbB2 is 2 nM, 6 nM respectively.